|
US20070014787A1
(en)
*
|
1998-07-15 |
2007-01-18 |
Human Genome Sciences, Inc. |
71 human secreted proteins
|
|
US7479555B2
(en)
|
1999-07-21 |
2009-01-20 |
Ceres, Inc. |
Polynucleotides having a nucleotide sequence that encodes a polypeptide having MOV34 family activity
|
|
US8044259B2
(en)
|
2000-08-03 |
2011-10-25 |
The Regents Of The University Of Michigan |
Determining the capability of a test compound to affect solid tumor stem cells
|
|
US6984522B2
(en)
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
|
US7431923B2
(en)
|
2005-01-03 |
2008-10-07 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
|
US7534429B2
(en)
|
2000-11-29 |
2009-05-19 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
|
US7442777B2
(en)
|
2000-11-29 |
2008-10-28 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
|
EP1448600A4
(en)
|
2001-09-07 |
2004-12-22 |
Bristol Myers Squibb Co |
POLYNUCLEOTIDE ENCODING A NOVEL HUMAN G PROTEIN-RELATED RECEPTOR, HGPRMBY39
|
|
US7678889B2
(en)
*
|
2002-08-06 |
2010-03-16 |
Diadexus, Inc. |
Compositions and methods relating to ovarian specific genes and proteins
|
|
US20050037946A1
(en)
*
|
2003-01-13 |
2005-02-17 |
Millennium Pharmaceuticals, Inc. |
Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 or 2419
|
|
US7094572B2
(en)
|
2003-03-14 |
2006-08-22 |
Bristol-Myers Squibb |
Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
|
|
ITRM20030149A1
(it)
|
2003-04-02 |
2004-10-03 |
Giuliani Spa |
Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
|
|
WO2005019258A2
(en)
*
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
US20050186577A1
(en)
|
2004-02-20 |
2005-08-25 |
Yixin Wang |
Breast cancer prognostics
|
|
WO2005121778A2
(en)
*
|
2004-06-14 |
2005-12-22 |
Galapagos N.V. |
Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases
|
|
US8288119B2
(en)
|
2004-06-21 |
2012-10-16 |
Exelixis, Inc. |
PGDS as modifiers of the PTEN pathway and methods of use
|
|
WO2006006477A1
(ja)
*
|
2004-07-09 |
2006-01-19 |
Shionogi & Co., Ltd. |
骨疾患又は関節疾患に関与するポリペプチド及びそのｄｎａ
|
|
US20110009326A1
(en)
*
|
2004-07-16 |
2011-01-13 |
Yves Raymond |
Methods or use of lamin b1 nuclear antigen, fragments and compositions thereof, for inhibiting or reducing a thrombotic event
|
|
EP1835933A4
(en)
*
|
2005-01-04 |
2015-01-07 |
Yeda Res & Dev |
HSP60, HSP60-PEPTIDES AND T-CELL VACCINES FOR IMMUNOMODULATION
|
|
AU2006216715A1
(en)
|
2005-02-22 |
2006-08-31 |
Ceres Inc. |
Modulating plant alkaloids
|
|
WO2006090389A2
(en)
|
2005-02-24 |
2006-08-31 |
Compugen Ltd. |
Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
|
|
GB0510627D0
(en)
|
2005-05-25 |
2005-06-29 |
Avidex Ltd |
Polypeptides
|
|
WO2006133461A1
(en)
|
2005-06-08 |
2006-12-14 |
Ceres Inc. |
Identification of terpenoid-biosynthesis related regulatory protein-regulatory region associations
|
|
US7713521B2
(en)
*
|
2005-08-12 |
2010-05-11 |
Schering Corporation |
MCP1 fusions
|
|
GB0519376D0
(en)
*
|
2005-09-23 |
2005-11-02 |
Astrazeneca Ab |
Diagnostic method
|
|
US8110184B2
(en)
*
|
2005-09-30 |
2012-02-07 |
University Of Kentucky Research Foundation |
Ex vivo and in vivo methods and related compositions for generating hematopoietic stem cell populations
|
|
US7723112B2
(en)
|
2005-10-31 |
2010-05-25 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
|
US20070192885A1
(en)
*
|
2006-01-26 |
2007-08-16 |
Daniel Chelsky |
TAT-039 and methods of assessing and treating cancer
|
|
EP2311478B1
(en)
|
2006-03-20 |
2014-07-16 |
Japan Science and Technology Agency |
Use of ip3 receptor-binding protein for controlling intracellular pH
|
|
JP5146944B2
(ja)
*
|
2006-03-20 |
2013-02-20 |
独立行政法人理化学研究所 |
Ｉｐ３受容体結合タンパク質による細胞内標的分子の制御
|
|
TW200808347A
(en)
|
2006-03-23 |
2008-02-16 |
Kirin Brewery |
Agonistic antibody directed against human thrombopoietin receptor
|
|
US20070237713A1
(en)
|
2006-04-04 |
2007-10-11 |
Fan Rong A |
PCan065 Antibody Compositions and Methods of Use
|
|
WO2007145840A2
(en)
*
|
2006-06-13 |
2007-12-21 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
|
JP4997547B2
(ja)
*
|
2006-06-15 |
2012-08-08 |
独立行政法人理化学研究所 |
炎症性疾患の判定方法
|
|
FR2908654B1
(fr)
*
|
2006-11-20 |
2014-04-04 |
Oreal |
Utilisation cosmetique de proteines de type chitinase
|
|
JP2010510797A
(ja)
*
|
2006-11-29 |
2010-04-08 |
メディカル リサーチ カウンシル |
アッセイ
|
|
WO2008079406A2
(en)
*
|
2006-12-19 |
2008-07-03 |
Genentech, Inc. |
Gene expression markers for inflammatory bowel disease
|
|
WO2008092002A2
(en)
|
2007-01-24 |
2008-07-31 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing pancreatic cancer
|
|
AU2008209482B2
(en)
|
2007-01-24 |
2014-05-01 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
|
WO2008092214A1
(en)
*
|
2007-02-02 |
2008-08-07 |
Minomic International Limited |
Biomarkers for diabetes
|
|
US20090208491A1
(en)
*
|
2007-02-14 |
2009-08-20 |
Austin Gurney |
Compositions and Methods for Diagnosing and Treating Cancer
|
|
WO2008111634A1
(ja)
*
|
2007-03-15 |
2008-09-18 |
Reverse Proteomics Research Institute Co., Ltd. |
脳・神経に特異的あるいは神経分化に特異的なバイオマーカー
|
|
WO2008156685A2
(en)
*
|
2007-06-14 |
2008-12-24 |
Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health |
Tendon stem cells
|
|
WO2009026622A1
(en)
*
|
2007-08-24 |
2009-03-05 |
Mylexa Pty Limited |
Modulators of hypersensitivity reactions
|
|
JP2009055838A
(ja)
*
|
2007-08-31 |
2009-03-19 |
Nipro Corp |
融合タンパク質、該融合タンパク質に関連する遺伝子、ベクター、形質転換体及び抗炎症性医薬組成物
|
|
MX2010013333A
(es)
|
2008-06-04 |
2011-04-05 |
Amgen Inc |
Mutantes fgf21 y usos de los mismos.
|
|
CA2729602A1
(en)
|
2008-07-08 |
2010-01-14 |
Oncomed Pharmaceuticals, Inc. |
Notch1 receptor binding agents and methods of use thereof
|
|
US9132189B2
(en)
|
2008-07-08 |
2015-09-15 |
Oncomed Pharmaceuticals, Inc. |
Notch1 binding agents and methods of use thereof
|
|
EA032727B1
(ru)
|
2008-10-10 |
2019-07-31 |
Амген Инк. |
Мутантный резистентный к протеолизу полипептид fgf21 и его применение
|
|
AU2009308707A1
(en)
|
2008-10-31 |
2010-05-06 |
Biogen Idec Ma Inc. |
LIGHT targeting molecules and uses thereof
|
|
BRPI0922820A2
(pt)
|
2008-12-04 |
2015-12-22 |
Sanofi Sa |
métodos e usos envolvendo a proteína de ligação ao heme 1
|
|
EP2865689A1
(en)
|
2008-12-08 |
2015-04-29 |
Compugen Ltd. |
FAM26F polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
|
US20120052069A1
(en)
|
2009-05-05 |
2012-03-01 |
Amgen Inc |
Fgf21 mutants and uses thereof
|
|
TWI560197B
(en)
|
2009-05-05 |
2016-12-01 |
Amgen Inc |
Fgf21 mutants and uses thereof
|
|
US20100285583A1
(en)
*
|
2009-05-08 |
2010-11-11 |
Capelluto Daniel G S |
Compounds and methods for inhibiting platelet aggregation
|
|
WO2010141999A1
(en)
*
|
2009-06-12 |
2010-12-16 |
The University Of Queensland |
Agents and methods for diagnosing and treating ankylosing spondylitis
|
|
WO2010148142A1
(en)
|
2009-06-17 |
2010-12-23 |
Amgen Inc. |
Chimeric fgf19 polypeptides and uses thereof
|
|
DK3202898T3
(en)
|
2009-11-02 |
2019-01-14 |
Univ Washington |
THERAPEUTIC NUCLEASE COMPOSITIONS AND PROCEDURES
|
|
JP2013512672A
(ja)
*
|
2009-12-02 |
2013-04-18 |
アムジエン・インコーポレーテツド |
ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質
|
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
|
WO2011088215A2
(en)
|
2010-01-13 |
2011-07-21 |
Oncomed Pharmaceuticals, Inc. |
Notch1 binding agents and methods of use thereof
|
|
EP2517049B1
(en)
|
2010-01-28 |
2014-01-08 |
Canon Kabushiki Kaisha |
Scintillator crystal body, method for manufacturing the same, and radiation detector
|
|
CA2695337A1
(en)
*
|
2010-03-04 |
2011-09-04 |
Ian De Belle |
Compositions and methods for inhibition of hiv
|
|
US8524217B2
(en)
|
2010-05-11 |
2013-09-03 |
Merck Sharp & Dohme Corp. |
MCP1-Ig fusion variants
|
|
US8775146B2
(en)
|
2010-07-22 |
2014-07-08 |
Shire Human Genetic Therapies, Inc. |
Crystal structure of human alpha-N-acetylglucosaminidase
|
|
EA037063B1
(ru)
|
2010-11-08 |
2021-02-01 |
Аблинкс Н.В. |
Cxcr2-связывающие полипептиды
|
|
IT1406405B1
(it)
*
|
2010-12-27 |
2014-02-21 |
Univ Roma |
Molecole peptidiche per il trattamento di patologie mitocondriali
|
|
WO2012090150A2
(en)
*
|
2010-12-27 |
2012-07-05 |
Compugen Ltd |
New cell-penetrating peptides and uses thereof
|
|
PH12013502441B1
(en)
|
2011-04-29 |
2019-02-08 |
Univ Washington |
Therapeutic nuclease compositions and methods
|
|
KR20140045409A
(ko)
*
|
2011-05-13 |
2014-04-16 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
초기 류마티스성 관절염의 진단 방법
|
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
|
CA2890571A1
(en)
|
2012-11-07 |
2014-05-15 |
Kenneth G. Geles |
Anti-notch3 antibodies and antibody-drug conjugates
|
|
CA2896076C
(en)
|
2012-12-21 |
2022-12-06 |
Aveo Pharmaceuticals, Inc. |
Anti-gdf15 antibodies
|
|
US9944700B2
(en)
|
2013-03-13 |
2018-04-17 |
Novartis Ag |
Notch2 binding molecules for treating respiratory diseases
|
|
SI3063275T1
(sl)
|
2013-10-31 |
2020-02-28 |
Resolve Therapeutics, Llc |
Terapevtske fuzije nukleaza-albumin in postopki
|
|
CN106061501A
(zh)
*
|
2013-12-29 |
2016-10-26 |
Cl昂科莱吉有限公司 |
用于治疗和预防炎症相关疾病的涉及p62/sqstm1的方法和组合物
|
|
EP3133400B1
(en)
*
|
2014-04-18 |
2021-06-09 |
Yantai Ju Jie Bioengineering Limited Company |
Use of ak6 and gpx5 male fertility related proteins or combination thereof
|
|
SG10201913611QA
(en)
|
2014-08-08 |
2020-03-30 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
|
GB201508025D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Fabry disease gene therapy
|
|
EP4059516A1
(en)
|
2016-04-22 |
2022-09-21 |
Vaccinex, Inc. |
Integral membrane protein display on poxvirus extracellular enveloped virions
|
|
AU2017290389B2
(en)
|
2016-07-01 |
2024-09-26 |
Resolve Therapeutics, Llc |
Optimized binuclease fusions and methods
|
|
KR102033215B1
(ko)
*
|
2016-07-05 |
2019-10-16 |
성균관대학교산학협력단 |
건선 유발 동물 모델 및 이의 용도
|
|
GB201700567D0
(en)
|
2017-01-12 |
2017-03-01 |
Genagon Therapeutics Ab |
Therapeutic agents
|
|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
|
US12359184B2
(en)
*
|
2017-05-24 |
2025-07-15 |
Thoeris Gmbh |
Use of glutamine synthetase for treating hyperammonemia
|
|
TWI868807B
(zh)
|
2017-08-03 |
2025-01-01 |
美商阿列克特有限責任公司 |
抗trem2抗體及其使用方法
|
|
US10947295B2
(en)
|
2017-08-22 |
2021-03-16 |
Sanabio, Llc |
Heterodimers of soluble interferon receptors and uses thereof
|
|
EP3856260A1
(en)
|
2018-09-28 |
2021-08-04 |
President and Fellows of Harvard College |
Mutant reverse tetracycline transactivators for expression of genes
|
|
US12274733B2
(en)
|
2018-09-28 |
2025-04-15 |
President And Fellows Of Harvard College |
Cellular reprogramming to reverse aging and promote organ and tissue regeneration
|
|
EP3856226B1
(en)
|
2018-09-28 |
2026-02-18 |
President and Fellows of Harvard College |
Cellular reprogramming to reverse aging and promote organ and tissue regeneration
|
|
EP3870974A1
(en)
*
|
2018-10-22 |
2021-09-01 |
F. Hoffmann-La Roche AG |
Profiling of rheumatoid arthritis autoantibody repertoire and peptide classifiers therefor
|
|
WO2020178426A1
(en)
*
|
2019-03-07 |
2020-09-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New vaccinal strategy to prevent or treat rheumatoid arthritis
|
|
WO2021148411A1
(en)
*
|
2020-01-21 |
2021-07-29 |
Boehringer Ingelheim International Gmbh |
Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure
|
|
US20250270278A1
(en)
*
|
2020-12-07 |
2025-08-28 |
The Research Foundation For The State University Of New York |
Methods of making water-soluble protein formed in a bacterial expression system, compositions, and methods of use thereof
|
|
US12252518B2
(en)
|
2023-01-06 |
2025-03-18 |
Life Biosciences, Inc. |
Methods of treating non-arteritic anterior ischemic optic neuropathy
|
|
WO2024231931A1
(en)
*
|
2023-05-08 |
2024-11-14 |
Canopy Immuno-Therapeutics Ltd. |
Ig-like fusion proteins for treating immune thrombocytopenia
|
|
US20250108088A1
(en)
*
|
2023-10-02 |
2025-04-03 |
Matice BioSciences, Inc. |
Regenerative peptides and methods for use thereof
|